Cancer Research UK

Unlike a traditional endowment that draws down a fixed corpus, Cancer Research UK relies on a diversified, recurring income base: public donations, retail charity shop profits, corporate partnerships, legacy gifts, and commercial royalties from intellectual property. This royalty stream — generated by drugs developed from CRUK-funded discoveries — recycles directly back into the research budget, creating a self-sustaining funding loop independent of annual fundraising volatility. The commercial arm, Cancer Research Horizons, structures equity and licensing deals to maximize long-term income for the charity's mission.

Cancer Research Horizons is the in-house commercialization and venture-building entity. It identifies commercially promising research from CRUK-funded labs, files patents, and either licenses those assets to pharmaceutical companies or spins them out as stand-alone biotech companies in which the charity retains equity. This structure gives CRUK direct financial exposure to the success of therapies it funds — effectively functioning as an evergreen venture investor. Royalties from marketed drugs flow back to the charity to fund the next cycle of discovery.

The Council of Trustees, chaired by Lord Simon Stevens, holds ultimate fiduciary responsibility. The Honorary Treasurer, Dr Robert Easton, brings direct private-equity experience to the role — Easton was formerly a Managing Director and Partner at The Carlyle Group, where he co-led the European buyout team. His oversight of the charity's financial and commercial strategy signals a governance approach that treats intellectual property and spin-out equity with the discipline of a professional investment portfolio. Day-to-day commercial decisions are executed through Cancer Research Horizons' management team.

The Francis Crick Institute is a major co-funded research partnership where Cancer Research UK is one of the primary founding supporters alongside the Medical Research Council, Wellcome Trust, and university partners. CRUK provides core funding and supports specific research programs housed at the Crick. More importantly, the Crick serves as a translational bridge — discoveries made there with CRUK backing are channeled into Cancer Research Horizons for patenting and spin-out formation, creating a pipeline that moves from fundamental biology to investable biotech companies.

It does both. The charity awards traditional research grants to academic investigators and core infrastructure grants to its institutes. However, through Cancer Research Horizons, it also takes equity stakes and negotiates royalty rights in spin-out companies built on CRUK-funded intellectual property. This dual posture — grant-maker and venture investor — is structurally unusual for a non-profit and is designed to capture returns from successful therapies that can be reinvested into further cancer research.

The Cancer Impact Club is a philanthropic community for high-net-worth individuals and donors who commit to multi-year, unrestricted funding for CRUK's highest-priority research. Membership provides access to scientific briefings, lab visits, and engagement with leading oncology researchers. It functions as a curated donor circle — similar in structure to Tiger 21 or R360 in the private-wealth world — but strictly focused on accelerating cancer research funding. The club complements retail fundraising and legacy giving by targeting concentrated major gifts.

Beyond the intellectual property and spin-out equity portfolio managed by Cancer Research Horizons, the charity holds a UK-wide network of over 550 retail shops generating operating income, and owns several real estate assets including its Stratford headquarters in London and core research institutes in Cambridge, Glasgow, and Manchester. The Cambridge Institute at the Li Ka Shing Centre and the Scotland Institute on the Garscube Estate represent significant physical infrastructure dedicated to oncology research.